Search ScienceDirect Q Advanced

Herb-drug interaction prediction based on the ... Toxicology and Applied Pharmacology, Volume 277, Is...

European Journal of Pharmacology, Volume 740, 2014...

1 2 Next >

Activity of antibacterial, antiviral, anti-infla

Purchase PDF

Purchase PDF

Citing articles (55)

Article Metrics

Citation Indexes Clinical Citations

Citations

Captures

Mentions

Exports-Saves

News Mentions

Social Media

©PLUMX

Shares, Likes & Comments:

ev of malaria prophylactic r..

View details ∨

View details ✓

91





to view subscribed content from hom



Phytomedicine

A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmColdTM) in patients with uncomplicated upper respiratory tract infection

R.C. Saxena a , R. Singh b , P. Kumar c , S.C. Yadav c , M.P.S. Negi d , V.S. Saxena e , A.J. Joshua f $\stackrel{\boxtimes}{\sim}$ $\stackrel{\boxtimes}{\sim}$, V. Vijay

Show more V

≪ Share 🥦 Cite

https://doi.org/10.1016/j.phymed.2009.12.001 Get rights and conter

A randomized, double blind placebo controlled clinical study was conducted to evaluate the efficacy of KalmCold $^{\mathrm{TM}}$, an extract of Andrographis paniculata, in patients with uncomplicated upper respiratory tract in fection (URTI). The assessment $% \left(1\right) =\left(1\right$ involved quantification of symptom scores by Visual Analogue Scale. Nine self evaluated symptoms of cough, expectoration, nasal discharge, headache, fever, sore throat, earache, malaise/fatigue and sleep disturbance were scored. A total of 223 patients of both sexes were randomized in two groups which received either $KalmCold^{\text{TM}}~(200~mg/day)~or~placebo~in~a~double~blind~manner.~In~both~the~treatments, mean~scores~of~all~symptoms~showed~a~decreasing~trend~from~day~1~to~day~$ day 3 but from day 3 to day 5 most of the symptoms in placebo treated group either remained unchanged (cough, headache and earache) or got aggravated (sore throat and sleep disturbance) whereas in KalmCold $^{\scriptscriptstyle \mathrm{TM}}$ treated group all symptoms showed a decreasing trend. Within groups, mean scores of symptoms in both the groups decreased significantly (p \leq 0.05) from day 1 to day 3 and day 5 while from day 3 to day 5 all symptoms except expectoration in placebo group did not improve significantly whereas in KalmCold $^{\scriptscriptstyle \mathrm{TM}}$ treated group all symptoms improved significantly (p \leq 0.05) except earache. Comparing mean between both groups, all symptoms at day 1 and day 3 were found to be the same while at day 5 all symptoms except earache in KalmColdTM treated group improved significantly (p \leq 0.05) than placebo group. Similarly, within groups, overall scores of all symptoms in both the groups decreased significantly (p \leq 0.05) from day 1 to day 3 and day 5 while from day 3 to day 5 placebo group did not improve significantly whereas KalmCold $^{\scriptscriptstyle \mathrm{TM}}$ treated group showed significant improvement (p \leq 0.05). On between groups analysis, KalmColdTM group showed significant reduction ($p \le 0.05$) in overall symptom scores as compared to placebo group. In both placebo and KalmCold $^{\mbox{\tiny TM}}$ treated groups, there were only a few minor adverse effects with no significant difference in occurrence (Z = 0.63; p > 0.05). The comparison of overall efficacy of KalmCold[™] over placebo was found to be significant (p \leq 0.05) and it was 2.1 times (52.7%) higher than placebo. The findings of this study revealed that KalmCold $^{\rm TM}$ was effective in reducing symptoms of upper respiratory tract infection





Keywords

 $\textit{Andrographis paniculata}; \textbf{KalmCold}^{\texttt{TM}}; \textbf{Upper respiratory tract infection}; \textbf{Common respiratory tract infection}; \textbf{Commo$ cold; Efficacy; Double blind placebo controlled trial



ScienceDirect

Outline

Abstract

Results

Acknowledge

Show full outline

Figures (1)

Tables (3)

■ Table 1

∏ Table 2

Table 3

Remote access Shopping cart Advertise Contact and support Terms and conditions View full text We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the **use of cookies**. Copyright © 2020 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V. Copyright © 2010 Elsevier GmbH. All rights reserved. eDirect ® is a registered trademark of Elsevier B.V.



≪ RELX™